INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)

Name: INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)
Uploaded: 2025-11-14T17:00:00+00:00
Description: Jerrold L. Vitek, MD, PhD, Head of the Neurology Department at the University of Minnesota, Minneapolis, MN, provides an overview of the INTREPID clinical

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Neuroimaging: Clinical Impact of Imaging Findings
Neuroimaging: Clinical Impact of Imaging Findings
Imaging & Testing
Neuroimaging: Clinical Impact of Imaging Findings
Laszlo Mechtler, MD, FAAN, FEAN, FASN, FAHS
Laszlo Mechtler, MD, FAAN, FEAN, FASN, FAHS
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
Alzheimer Disease & Dementias
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
Microplastics and "Negative Neuroplasticity": An Emerging Topic in Clinical Neurology
Microplastics and "Negative Neuroplasticity": An Emerging Topic in Clinical Neurology
Practice Management
Microplastics and "Negative Neuroplasticity": An Emerging Topic in Clinical Neurology
Keshav Shah, MBBS; David Davis, PhD
Keshav Shah, MBBS; David Davis, PhD
Diagnosis and Management of Dementia and Psychosis in Individuals With Parkinson Disease
Diagnosis and Management of Dementia and Psychosis in Individuals With Parkinson Disease
Movement Disorders
Diagnosis and Management of Dementia and Psychosis in Individuals With Parkinson Disease
Jorge Patino, MD
Jorge Patino, MD